Literature DB >> 29602706

Baseline lung allograft dysfunction is associated with impaired survival after double-lung transplantation.

Jonathan Liu1, Kathy Jackson1, Justin Weinkauf2, Ali Kapasi2, Alim Hirji2, Steve Meyer3, John Mullen3, Jayan Nagendran3, Dale Lien2, Kieran Halloran4.   

Abstract

BACKGROUND: The prognostic value of defining normal vs abnormal baseline post-transplant lung function (or baseline lung allograft dysfunction [BLAD]) has not been studied using standardized reference values of percent predicted of the population. Our aim was to assess the association between BLAD and survival in double-lung transplant recipients and assess for potential pre-transplant donor and recipient risk factors for BLAD.
METHODS: We conducted a retrospective cohort study of double-lung transplant recipients in our program during the period 2004 to 2009. We defined normal baseline function as both forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) ≥80% predicted on at least 2 consecutive tests ≥3 weeks apart; we defined BLAD as failure to meet these criteria. We used a Cox regression model to assess the association between BLAD and survival. We used logistic regression to assess potential pre-transplant donor and recipient factors associated with BLAD.
RESULTS: Of 178 patients double-lung transplant recipients eligible for study, 75 (42%) met the criteria for BLAD. BLAD was associated with impaired survival (hazard ratio [HR] 2.23, 95% confidence interval [CI] 1.41 to 3.54]) via Cox regression compared to patients with normal baseline, and lower baseline was associated with greater risk of death in a dose-dependent fashion. Pre-transplant factors associated with BLAD included interstitial lung disease (ILD) as an indication for transplant (odds ratio [OR] 2.66, 95% CI 1.17 to 6.15) and heavy donor smoking history (OR 3.07, 95% CI 1.17 to 8.43).
CONCLUSIONS: BLAD is dynamic risk state associated with impaired survival after double-lung transplantation, and should be considered when physiologically phenotyping patients.
Copyright © 2018 International Society for the Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  chronic lung allograft dysfunction; lung physiology; lung transplantation; mortality; outcomes

Mesh:

Year:  2018        PMID: 29602706     DOI: 10.1016/j.healun.2018.02.014

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  3 in total

1.  Body Mass Index Recovery after Lung Transplant for Cystic Fibrosis.

Authors:  Joseph B Pryor; Miranda C Bradford; Ann L Jennerich; Travis Y Hee Wai; Joseph M Pilewski; Siddhartha G Kapnadak; Moira L Aitken; Christopher H Goss; Kathleen J Ramos
Journal:  Ann Am Thorac Soc       Date:  2022-07

2.  IL-6 receptor blockade for allograft dysfunction after lung transplantation in a patient with COPA syndrome.

Authors:  Peter Riddell; Sajad Moshkelgosha; Liran Levy; Nina Chang; Prodipto Pal; Kieran Halloran; Phil Halloran; Michael Parkes; Lianne G Singer; Shaf Keshavjee; Tereza Martinu; Stephen C Juvet
Journal:  Clin Transl Immunology       Date:  2021-01-28

3.  Utility of bile acids in large airway bronchial wash versus bronchoalveolar lavage as biomarkers of microaspiration in lung transplant recipients: a retrospective cohort study.

Authors:  Chen Yang Kevin Zhang; Musawir Ahmed; Ella Huszti; Liran Levy; Sarah E Hunter; Kristen M Boonstra; Sajad Moshkelgosha; Andrew T Sage; Sassan Azad; Rasheed Ghany; Jonathan C Yeung; Oscar M Crespin; Lianne G Singer; Shaf Keshavjee; Tereza Martinu
Journal:  Respir Res       Date:  2022-08-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.